NCT04597697View on ClinicalTrials.gov

A Study to Test How a New Long-acting Insulin (Insulin Icodec) Works in the Body of People With Liver Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 22, 2020

Primary Completion Date

March 24, 2022

Study Completion Date

March 24, 2022

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Insulin icodec

Insulin icodec will be investigated in participants with impaired liver function and subjects with normal liver function. Administered as a single dose subcutaneously (under the skin) The study will last for about 8 weeks.

Trial Locations (2)

17000

Pharmaceutical Research Associates CZ, s.r.o., Prague

83101

Summit Clinical Research s.r.o., Bratislava

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT04597697 - A Study to Test How a New Long-acting Insulin (Insulin Icodec) Works in the Body of People With Liver Disease | Biotech Hunter | Biotech Hunter